| Expression pattern: |
UP |
| Associated gene: |
CDH6, METTL14 |
| Associated microRNA: |
miR-1233-3p |
| Biological function: |
Promotes NSCLC cell proliferation, migration, invasion, tumor growth, metastasis and EMT; circ_0000517 silencing inhibits these malignant phenotypes. |
| Molecular mechanism: |
METTL14-mediated m6A modification increases circ_0000517 RNA stability, leading to upregulation; cytoplasmic circ_0000517 functions as a ceRNA that sponges miR-1233-3p to increase CDH6 expression and promote EMT and malignant progression in NSCLC. |
| Biological pathway or process: |
m6A modification (promotes); mRNA stability (promotes); ceRNA regulation (promotes); proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); EMT (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; Clinical Sample Validation; Nuclear-Cytoplasmic Fractionation; Transfection; CCK8; Colony Formation Assay; Wound Healing Assay; Transwell Assay; In Vivo Animal Model; Bioinformatics Analysis; MeRIP / MeRIP-seq; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Actinomycin D / DRB Stability Assay; Western Blot |
| Clinical significance: |
circ_0000517 may serve as a promising therapeutic target and potential predictor for NSCLC prognosis. |
| Description: |
circ_0000517 is up-regulated in NSCLC tissues and cell lines and acts as an oncogenic circRNA. METTL14-mediated m6A modification stabilizes circ_0000517, while cytoplasmic circ_0000517 sponges miR-1233-3p to increase CDH6 expression, promoting proliferation, migration, invasion, tumor growth and EMT. The study suggests circ_0000517 as a potential therapeutic target in NSCLC. |
| Confidence score: |
0.807 |